Business Wire

VA-REGULA

25.7.2024 08:01:30 CEST | Business Wire | Press release

Share
Securing the Olympics 2024: Effective Identity Verification for International Guests

Regula, a global developer of forensic devices and identity verification solutions, prepared a dedicated package of expert articles focused on document verification, tailored to meet the needs of carriers, border verification authorities, the hospitality industry, and businesses during the 2024 Olympics. These resources aim to address the unique challenges posed by the influx of international visitors, ensuring seamless and secure experiences for all.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724663488/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Effective Identity Verification for the Olympics 2024: how is it done? Regula's vision (Graphic: Regula)

France anticipates a significant boost in tourism and economic activity during the 2024 Olympics, with over 10 million visitors projected to generate an estimated €3 billion in revenue. This massive surge in visitors will not only increase the risk of fraud targeting consumers and businesses but also pose substantial challenges for security and access management. The influx of international guests underscores the critical need for advanced and comprehensive Identity Verification (IDV) systems.

Properly verifying and authorizing everyone at every stage of their Olympic journey is essential for maintaining security and ensuring smooth access to event venues and services.

1. Addressing Carrier Requirements for Advance Passenger Information

With recent EU regulations mandating the collection of advance passenger information, carriers face unprecedented challenges. Our topic, "How Carriers Can Tackle New Requirements for Gathering Advance Passenger Information," provides comprehensive insights and practical solutions to help carriers comply with these regulations efficiently. As the Olympics are hosted in France, this information is crucial for ensuring smooth travel experiences for millions of visitors.

2. Professional Border Verification Techniques

Border control is a critical component of international events. Our resources include:

  • "How Regula Creates the Most Full and Detailed Document Reference System": An in-depth look at how Regula's advanced technology supports border control authorities with the most comprehensive document reference systems available. It contains templates of passports, ID cards, visas, banknotes, coins, driver’s licenses, and vehicle documents from all over the world.

These topics are designed to empower border officials with the knowledge and tools needed to maintain security while facilitating the flow of visitors.

3. Transforming Travel & Hospitality with Data Entry Automation

In the hospitality sector, efficient check-ins are vital for a positive guest experience. At the same time, manual entry of ID details in hotels can often cause long lines, messes, and delays.

Our topic, "How Data Entry Automation Transforms Travel & Hospitality," highlights the latest innovations in reader technology and software. It provides examples of automated check-in processes and calls to action for hospitality businesses to leverage these advancements for a competitive edge.

4. Solving Business Challenges of Foreign Documents Verification

Businesses are facing an increase in the number of international customers, and the smart ones start adapting to the challenges of verifying foreign documents. Our article, "Foreign ID Document Verification for Businesses,” offers practical advice and solutions for businesses to navigate these complexities, ensuring they can confidently verify the identities of international customers.

To get access to all the expert articles in one place, visit the landing page “Securing the Olympics 2024”.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724663488/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye